Literature DB >> 28224279

NP-59 test for preoperative localization of primary hyperaldosteronism.

Marcello Di Martino1, Iñigo García Sanz2, Jose Luis Muñoz de Nova2, Cristina Marín Campos2, Miguel Martínez Martín2, Luis Domínguez Gadea2.   

Abstract

PURPOSE: Adrenal venous sampling is generally considered the gold standard to identify unilateral hormone production in cases of primary hyperaldosteronism. The aim of this study is to evaluate whether the iodine-131-6-β-iodomethyl-19-norcholesterol (NP-59) test may represent an alternative in selected cases.
METHODS: Patients submitted to laparoscopic adrenalectomy for suspected primary hyperaldosteronism (n = 27) were retrospectively reviewed. When nuclear medicine tests were preoperatively performed, their results were compared with the histopathologic findings and clinical improvement.
RESULTS: Nuclear medicine tests were realized in 13 patients. In 11 (84.6%), a planar anterior and posterior NP-59 scintigraphy was performed and a SPECT/TC in two (15.4%). Scintigraphy indicated a preoperative lateralization in 12 out of 13 patients (92.3%). When the value of NP-59 tests was based on pathologic results, it showed a sensitivity of 90.9% and a positive predictive value of 83.3%. When the nuclear medicine test's performance was based on postoperative blood pressure control, both sensitivity and positive predictive value were 91.6%.
CONCLUSIONS: Nuclear medicine tests represent a useful tool in the preoperative localisation of primary hyperaldosteronism with a high sensitivity and positive predictive value. In patients with contraindications to adrenal venous sampling like contrast allergies, or when it is inconclusive, scintigraphy can represent a useful and non-invasive alternative.

Entities:  

Keywords:  Adrenal adenoma; NP-59 SPECT/TC; NP-59 scintigraphy; Primary hyperaldosteronism

Mesh:

Substances:

Year:  2017        PMID: 28224279     DOI: 10.1007/s00423-017-1561-1

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  28 in total

Review 1.  Diagnosis and management of primary aldosteronism: an updated review.

Authors:  Chia-Ter Chao; Vin-Cent Wu; Chin-Chi Kuo; Yen-Hung Lin; Chin-Chen Chang; S Jeff Chueh; Kwan-Dun Wu; Eduardo Pimenta; Michael Stowasser
Journal:  Ann Med       Date:  2013-05-23       Impact factor: 4.709

Review 2.  Primary aldosteronism.

Authors:  Robert M Carey
Journal:  J Surg Oncol       Date:  2012-07-17       Impact factor: 3.454

3.  Diagnostic accuracy and pitfalls of [iodine-131]6-beta-iodomethyl-19-norcholesterol (NP-59) imaging.

Authors:  E A Kazerooni; J C Sisson; B Shapiro; M D Gross; A Driedger; G A Hurwitz; A G Mattar; N A Petry
Journal:  J Nucl Med       Date:  1990-04       Impact factor: 10.057

4.  A new and superior adrenal imaging agent, 131I-6beta-iodomethyl-19-nor-cholesterol (NP-59): evaluation in humans.

Authors:  S D Sarkar; E L Cohen; W H Beierwaltes; R D Ice; R Cooper; E N Gold
Journal:  J Clin Endocrinol Metab       Date:  1977-08       Impact factor: 5.958

5.  Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas.

Authors:  Timothy J Burton; Isla S Mackenzie; Kottekkattu Balan; Brendan Koo; Nick Bird; Dmitri V Soloviev; Elena A B Azizan; Franklin Aigbirhio; Mark Gurnell; Morris J Brown
Journal:  J Clin Endocrinol Metab       Date:  2011-11-23       Impact factor: 5.958

6.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

7.  131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results.

Authors:  Ruoh-Fang Yen; Vin-Cent Wu; Kao-Lang Liu; Mei-Fang Cheng; Yen-Wen Wu; Shih-Chieh Chueh; Wei-Chou Lin; Kwan-Dun Wu; Kai-Yuan Tzen; Ching-Chu Lu
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

Review 8.  Management of hypertension in primary aldosteronism.

Authors:  Anna Aronova; Thomas J Fahey; Rasa Zarnegar
Journal:  World J Cardiol       Date:  2014-05-26

9.  Scintigraphic localization of adrenal lesions in primary aldosteronism.

Authors:  M D Gross; B Shapiro; R J Grekin; J E Freitas; G Glazer; W H Beierwaltes; N W Thompson
Journal:  Am J Med       Date:  1984-11       Impact factor: 4.965

10.  Diagnostic value of I-131 NP-59 SPECT/CT scintigraphy in patients with subclinical or atypical features of primary aldosteronism.

Authors:  Yi-Chun Chen; Yu-Chieh Su; Chang-Kuo Wei; Jainn-Shiun Chiu; Chih-En Tseng; Shao-Jer Chen; Yuh-Feng Wang
Journal:  J Biomed Biotechnol       Date:  2011-04-07
View more
  3 in total

Review 1.  Topical Diagnosis and Determination of the Primary Hyperaldosteronism Variant.

Authors:  Viktor O Shidlovskyi; Olexandr V Shidlovskyi; Oleksandr A Tovkai; Michael I Sheremet; Vitaliy V Maksymyuk; Volodimir V Tarabanchuk; Shved M Ivanovych; Mykolaivna S Heryak; Mykhailovych S Andreychyn; Igorivna I Hanberher; Antonina A Piddubna
Journal:  J Med Life       Date:  2019 Oct-Dec

2.  Feasibility of Iodine-131 6β-Methyl-Iodo-19 Norcholesterol (NP-59) Scintigraphy to Complement Adrenal Venous Sampling in Management of Primary Aldosteronism: A Case Series.

Authors:  Jeongmin Lee; Jeonghoon Ha; Sang-Kuon Lee; Hye Lim Park; Sung-Hoon Kim; Dong-Jun Lim; Jung Min Lee; Sang-Ah Chang; Moo Il Kang; Min-Hee Kim
Journal:  Int J Gen Med       Date:  2021-03-01

Review 3.  Laboratory Diagnostics of Primary Hyperaldosteronism and its Peculiarities (Literature Review).

Authors:  Viktor O Shidlovskyi; Oleander V Shidlovskyi; Mikhail Sheremet; Igor V Zhulkevych; Sergyi M Andreychyn; Inna I Hanberher; Ivan I Smachylo; Volodimir B Dobrorodny; Yuryi M Futuima
Journal:  J Med Life       Date:  2019 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.